PR Newswire
LAS VEGAS, Feb. 12, 2026
The growth of the BCL-2 inhibitors market is expected to be driven primarily by rising incidence, increased awareness and access to treatment, and the launch of emerging drugs such as Lisaftoclax (Ascentage Pharma), Sonrotoclax (BeOne Medicines), LP-118 and LP-108 (Newave Pharmaceutical), and others, reports DelveInsight.
LAS VEGAS, Feb. 12, 2026 /PRNewswire/ — DelveInsight’s BCL-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Myelodysplastic Syndrome, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Waldenström’s Macroglobulinemia, Non-Hodgkin Lymphoma, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging BCL-2 inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Key Takeaways from the BCL-2 Inhibitors Market Report
- The total market size of BCL-2 inhibitors in the leading markets is expected to surge significantly by 2034.
- In 2024, the United States holds the largest share of the BCL-2 inhibitors market among the 7MM.
- The report provides the total potential number of patients in the indications, such as Myelodysplastic Syndrome, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Waldenström’s Macroglobulinemia, Non-Hodgkin Lymphoma, and others.
- In 2024, the total incident cases of multiple myeloma in the 7MM were around 76K.
- Leading BCL-2 inhibitors companies, such as Ascentage Pharma, BeOne Medicines, Newave Pharmaceutical, and others, are developing novel BCL-2 inhibitors that can be available in the BCL-2 inhibitors market in the coming years.
- Some of the key BCL-2 inhibitors in clinical trials include Lisaftoclax, Sonrotoclax, LP-118, LP-108, and others.
Discover how big is the BCL-2 inhibitors market in 2034 @ https://www.delveinsight.com/sample-request/bcl2-inhibitors-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the BCL-2 Inhibitors Market
- Rising Cancer Incidence: Growing prevalence of hematologic malignancies (e.g., chronic lymphocytic leukemia, acute myeloid leukemia) and solid tumors increases demand for targeted therapies.
- Increased Adoption of Targeted Therapies: Shift from chemotherapy to targeted and precision medicines is a major trend in oncology. BCL-2 inhibitors target the apoptotic resistance pathway, making them attractive for personalized treatment plans.
- Launch of Emerging Therapies: The dynamics of the BCL-2 inhibitors market are expected to change in the coming years due to the launch of emerging therapies such as Lisaftoclax (Ascentage Pharma), Sonrotoclax (BeOne Medicines), LP-118 and LP-108 (Newave Pharmaceutical), and others.
Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, noted that the BCL2 inhibitor market has experienced significant growth and attention, driven by its potential to treat various haematological diseases. With a large addressable patient base across the 7MM and a promising pipeline of candidates, the market is poised for substantial growth.
BCL-2 Inhibitors Market Analysis
- BCL-2 inhibitors are proving transformative when used in combination with other cancer therapies, enhancing therapeutic effectiveness and offering new hope for patients with challenging hematologic malignancies, such as CLL and AML.
- Venetoclax, the first FDA-approved specific inhibitor of BCL-2, is highly effective as monotherapy for CLL and mantle cell lymphoma (MCL) and is now part of frontline CLL treatment.
- Venetoclax demonstrates rapid and durable responses in elderly AML patients who are ineligible for intensive chemotherapy.
- Several next-generation BCL-2 inhibitors, such as Lisaftoclax (Ascentage Pharma), Sonrotoclax (BeOne Medicines), LP-118 and LP-108 (Newave Pharmaceutical), and others in clinical trials, aim to broaden efficacy across cancers, including non-Hodgkin lymphoma and multiple myeloma.
- Ongoing research is evaluating their role in solid tumors and developing next-generation agents, positioning BCL-2 inhibitors as key components of precision oncology.
- Their broad applicability across cancer types supports their emergence as essential tools in patient-centered, evolving cancer care strategies.
Learn more about who are the leading companies in BCL-2 inhibitors @ BCL-2 Inhibitors Analysis
BCL-2 Inhibitors Competitive Landscape
Some of the emerging BCL-2 inhibitors in the clinical trial landscape include Lisaftoclax (Ascentage Pharma), Sonrotoclax (BeOne Medicines), LP-118 and LP-108 (Newave Pharmaceutical), and others.
Ascentage Pharma’s Lisaftoclax (APG-2575) is an innovative, orally available small-molecule inhibitor that specifically blocks BCL-2, a key regulator of apoptosis often upregulated in blood cancers. By targeting this pathway, lisaftoclax demonstrates strong potential to undermine cancer cell survival. It has advanced to Phase III clinical trials for myelodysplastic syndrome and is being evaluated in multiple Phase I and II studies for additional hematologic malignancies, underscoring its broad therapeutic promise.
BeOne Medicines’ Sonrotoclax is an experimental small-molecule inhibitor of BCL-2 and part of the BH3 mimetic class. Compared with venetoclax, it exhibits greater potency and selectivity for BCL-2 over BCL-xL and may offer improved convenience in clinical use. The drug has been granted FDA Fast Track status for relapsed or refractory Waldenström’s macroglobulinemia and is currently in Phase II trials.
Newave Pharmaceuticals’ LP-108 is another next-generation oral BCL-2 inhibitor intended for treating a range of hematologic cancers, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and myelodysplastic syndromes (MDS). It is presently undergoing evaluation in Phase I clinical trials.
The anticipated launch of these emerging therapies are poised to transform the BCL-2 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the BCL-2 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about what is driving the growth in the BCL-2 inhibitors market, visit @ BCL-2 Inhibitors Treatment
Recent Developments in the BCL-2 Inhibitors Market
- In December 2025, Ascentage Pharma reported new findings from a Phase Ib/II trial of Lisaftoclax (APG-2575), one of its major investigational therapies, used in combination with azacitidine (AZA) in patients newly diagnosed with myeloid cancers or previously treated with venetoclax. The data were presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
- In November 2025, BeOne Medicines reported that the U.S. FDA had accepted its New Drug Application for sonrotoclax and assigned it Priority Review. The drug is a next-generation BCL2 inhibitor intended for adults with relapsed or refractory mantle cell lymphoma who have previously been treated with a BTK inhibitor.
- In October 2025, BeOne Medicines announced that the FDA had awarded Breakthrough Therapy Designation to sonrotoclax, a next-generation investigational BCL2 inhibitor that may be best in its class, for treating adults with relapsed or refractory mantle cell lymphoma
- In July 2025, Ascentage Pharma reported that China’s National Medical Products Administration (NMPA) had approved lisaftoclax (APG-2575), the company’s proprietary, next-generation Bcl-2-selective inhibitor, for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic treatment, including BTK inhibitors.
What are BCL-2 Inhibitors?
BCL-2 inhibitors are a class of anticancer drugs designed to block the activity of the BCL-2 protein, which helps cancer cells survive by preventing programmed cell death (apoptosis). In many cancers, such as certain leukemias and lymphomas, the BCL-2 protein is overproduced, allowing abnormal cells to live much longer than they should. By inhibiting BCL-2, these inhibitors restore the cell’s natural ability to undergo apoptosis, making cancer cells more vulnerable to treatment. One of the best-known examples is venetoclax, which has shown significant effectiveness in specific blood cancers. These drugs are targeted therapies that aim to treat cancer more precisely with fewer effects on healthy cells.
BCL-2 Inhibitors Epidemiology Segmentation
The BCL-2 inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020-2034 across the leading markets. The BCL-2 inhibitors target patient pool is segmented into:
- Total Cases of Selected Indications for BCL-2 Inhibitors
- Total Eligible Patient Pool for BCL-2 Inhibitors in Selected Indications
- Total Treated Cases in Selected Indications for BCL-2 Inhibitors
BCL-2 Inhibitors Report Metrics
Details
Study Period
2020-2034
BCL-2 Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report Myelodysplastic Syndrome, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia,
Waldenström’s Macroglobulinemia, Non-Hodgkin Lymphoma, and others
BCL-2 Inhibitors Target Patient Pool Segmentation Total Cases of Selected Indications for BCL-2 Inhibitors, Total Eligible Patient Pool for BCL-2
Inhibitors in Selected Indications, and Total Treated Cases in Selected Indications for BCL-2
Inhibitors
Key BCL-2 Inhibitors Companies
Ascentage Pharma, BeOne Medicines, Newave Pharmaceutical, AbbVie, Genentech, and others
Key BCL-2 Inhibitors
Lisaftoclax, Sonrotoclax, LP-118, LP-108, VENCLEXTA/VENCLYXTO, and others
Scope of the
BCL-2 Inhibitors
Market Report
- BCL-2 Inhibitors Therapeutic Assessment: BCL-2 Inhibitors’ current marketed and emerging therapies
- BCL-2 Inhibitors Market Dynamics: Conjoint Analysis of Emerging BCL-2 Inhibitors Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, BCL-2 Inhibitors Market Access and Reimbursement
Discover which BCL-2 inhibitors are in clinical trials @ BCL-2 Inhibitors Clinical Trials
Table of Contents
1
BCL-2 Inhibitors Market Key Insights
2
BCL-2 Inhibitors Market Report Introduction
3
Key Highlights of The Report
4
Executive Summary Of BCL 2 Inhibitors
5
Key Events
6
Epidemiology And Market Forecast Methodology
7
BCL 2 Inhibitors Market Overview At A Glance
7.1 Market Share (%) Distribution of BCL 2 Inhibitors By
Therapies in 2020
7.2 Market Share (%) Distribution of BCL 2 Inhibitors By
Therapies in 2034
7.3 Market Share (%) Distribution of BCL 2 Inhibitors By
Indications in 2020
7.4 Market Share (%) Distribution of BCL 2 Inhibitors By
Indications in 2034
8
Background And Overview
9
Epidemiology And Patient Population
9.1
Key Findings
9.2
Assumptions And Rationale
9.3
Total Cases by Indication in the 7MM
9.4 Total Eligible Patient Pool by Indications in the 7MM
9.5
Treatable Cases by Indication in the 7MM
9.4.1
United States
9.4.1.1
Cases by Indication in the United States
9.4.1.2 Total Eligible Patient Pool by Indications in the United
States
9.4.1.3 Treatable Cases by Indication in the United States
9.4.2
EU4 and the UK
9.4.3
Japan
10
Marketed BCL-2 Inhibitors
10.1
Key Competitors
10.2
VENCLEXTA/VENCLYXTO: AbbVie/Genentech
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Ongoing Clinical Development
10.2.5
Safety and Efficacy
11
Emerging BCL-2 Inhibitors
11.1
Key Competitors
11.2
Lisaftoclax: Ascentage Pharma
11.2.1
Product Description
11.2.2
Other Development Activities
11.2.3
Clinical Development
11.2.3.1
Clinical Trials Information
11.2.4
Safety and Efficacy
List to be continued…
12
BCL 2 Inhibitors Market: The 7MM Analysis
12.1
Key Findings
12.2
BCL-2 Inhibitors Market Outlook
12.3 Key BCL-2 Inhibitors Market Forecast Assumptions
12.4 Total Market Size of BCL 2 Inhibitors in the 7MM
12.5 Market Size of BCL 2 Inhibitors By Therapies In the 7MM
12.6
United States BCL-2 Inhibitors Market
12.6.1 Total Market Size of BCL 2 Inhibitors in the United
States
12.6.2 Market Size of BCL 2 Inhibitors By Therapies in the
United States
12.7
EU4 and the UK BCL-2 Inhibitors Market
12.8
Japan BCL-2 Inhibitors Market
12.8.1
Total Market Size of BCL 2 Inhibitors in Japan
12.8.2 Market Size of BCL 2 Inhibitors By Therapies in Japan
13
BCL-2 Inhibitors Market Unmet Needs
14
BCL-2 Inhibitors Market SWOT Analysis
15
KOL Views on BCL-2 Inhibitors
16 BCL-2 Inhibitors Market Access and Reimbursement
16.1
United States
16.2
EU4 and the UK
16.3
Japan
17
Bibliography
18
BCL-2 Inhibitors Market Report Methodology
Related Reports
Multiple Myeloma Market
Multiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies, including Sanofi, Karyopharm Therapeutics, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., and others.
Myelodysplastic Syndrome Market
Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast
– 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MDS companies, including Bristol-Myers Squibb, Astex Pharmaceutical, Taiho Oncology, Fibrogen, AbbVie, Gilead SciencesNovartis, Syros Pharmaceuticals, Takeda, Pfizer, Geron Corporation, Karyopharm Therapeutics, Antengene Corporation, BerGenBio ASA, Jazz Pharmaceuticals, Aprea Therapeutics, Sanofi, Medac, and others.
Non-Hodgkin’s Lymphoma Market
Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key non-hodgkin’s lymphoma companies, including ADC Therapeutics, Bristol-Myers Squibb, Roche, Amgen, Johnson & Johnson, Celgene Corp., Mesoblast, Genmab, Novartis, Teva Pharmaceutical Industries, Karyopharm Therapeutics, AB Science, Genentech, Eli Lilly and Company, Rafael Pharmaceuticals, IO Biotech, ImmuneOnco Biopharma, Chongqing Precision Biotech, Rhizen Pharmaceuticals, Nanjing Legend Biotech, Tokalas, Arvinas, MorphoSys AG, Shanghai Genechem, Guiguidan Biomedicine (Zhongshan), Corvus Pharmaceuticals, Evive Biotech, Kite Pharma, Pfizer, Gilead Sciences, TG Therapeutics, AstraZeneca, Bayer HealthCare Pharmaceuticals, Secura Bio, BeiGene, Xynomic Pharmaceuticals, Merck & Co. Inc., Epizyme, Nordic Nanovector, Artiva Biotherapeutics, Inc., Timmune Biotech, Forty Seven, Acerta Pharma, BioInvent International, Adagene, Juventas Cell Therapy, SystImmune, Molecular Templates, Apollomics, MEI Pharma, and others.
Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast
– 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key AML companies, including Daiichi Sankyo, Agios Pharma, Astellas Pharma, Rigel Pharmaceuticals, Jazz Pharmaceuticals, Novartis, Pfizer, Abbvie, BMS, Arog Pharmaceuticals, Actinium Pharmaceutical, Astex Pharmaceutical, Syndax, Geron, SELLAS Life Sciences, Johnson & Johnson Innovative Medicine, Sanofi, Affimed, Sumitomo Pharma, Kura Oncology, CULLINAN THERAPEUTICS, Molecular Partners, Caribou Biosciences, BioPath Holdings, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bcl-2-inhibitors-market-poised-for-robust-growth-during-the-forecast-period-20252034-as-oncology-pipelines-expand–delveinsight-302685937.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…